PDE9 Inhibitor Combination Therapy for Longer-Acting Psychedelics
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for psychiatric disorders such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and post-traumatic stress disorder (PTSD) using serotonergic psychedelic drugs like psilocybin and ketamine are limited by short-lived effects, high cost, and burdensome side effects, necessitating frequent administration and intensive monitoring.
Innovation Solution
Administering a therapeutically effective amount of a serotonergic psychedelic drug in conjunction with a phosphodiesterase type 9 (PDE9) inhibitor to enhance therapeutic effects, prolong biological activities, mitigate undesirable side effects, and reduce abuse potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If serotonergic psychedelic drugs are administered to treat psychiatric disorders, then therapeutic effects are achieved, but the duration of action is short requiring frequent administration
Solution Approach 1:
The patent combines serotonergic psychedelic drugs with PDE9 inhibitors in a single therapeutic regimen. The PDE9 inhibitor is administered concurrently or sequentially with the psychedelic drug to prolong its therapeutic effects. This combination allows the short-acting psychedelic to have extended duration of action through the mechanism of PDE9 inhibition, which prevents breakdown of cGMP and sustains neuronal plasticity changes.
Solution Approach 2:
The PDE9 inhibitor acts as an intermediary substance that modifies the pharmacokinetics and pharmacodynamics of the serotonergic psychedelic. By inhibiting PDE9 enzyme activity, the intermediary prevents degradation of cyclic nucleotides, thereby extending the effective window of the psychedelic's action without requiring direct modification of the psychedelic molecule itself.
2Reliability
If serotonergic psychedelic drugs are administered frequently to maintain therapeutic effects, then treatment efficacy is maintained, but treatment burden and cost increase
Solution Approach 1:
By merging the psychedelic drug with a PDE9 inhibitor in a single treatment protocol, the patent reduces the number of separate administrations needed. The PDE9 inhibitor extends the duration of each psychedelic dose, allowing less frequent dosing schedules while maintaining therapeutic efficacy, thereby reducing overall treatment burden.
Solution Approach 2:
The PDE9 inhibitor provides continuous enzymatic inhibition that sustains the therapeutic effects of the psychedelic drug between doses. This creates a more continuous useful action profile, preventing the rapid decline of therapeutic effects that would otherwise require frequent re-administration of the psychedelic.
3Reliability
If serotonergic psychedelic drugs are administered at higher doses to enhance therapeutic effects, then treatment efficacy improves, but side effects increase
Solution Approach 1:
The PDE9 inhibitor provides localized biochemical modification in specific brain regions where PDE9 is highly expressed, such as the striatum and cortex. This localized action allows the psychedelic to achieve enhanced therapeutic effects in target regions without proportionally increasing systemic side effects, as the PDE9 inhibition is concentrated where it is most beneficial for treating psychiatric disorders.
Data Source
AI summary
The present application provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a serotonergic psychedelic drug and a therapeutically effective amount of a phosphodiesterase type 9 inhibitor.